NSE · UNICHEMLAB
Unichem Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹402 Cr with net profit ₹1 Cr — a 0.37% net margin, versus 1.51% the period before.
Shareholding
As of 2026-09-30
- Promoter70.22%
- Public17.68%
- FII2.7%
- DII9.4%
26,164 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.47× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #41 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Unichem Laboratories Ltd.(this company) | ₹3,532 Cr | 29.72 | 1.27 | 4.27% | 14.3% |
AI analysis
AI-generated · google/gemini-2.5-flashUnichem Laboratories Ltd. (UNICHEMLAB) has a market capitalization of Rs 4193 Cr and is trading at a PE ratio of 51.21. The company reported revenue of Rs 2264.91 Cr with a growth of 18.3%. Its profit margin stands at 11.48%.
Positives
- +The promoter holding is substantial at 70.22% as of June 30, 2026.
- +The debt-to-equity ratio is low at 0.19.
- +Promoter shareholding is not pledged (0%).
- +Return on Equity is high at 288.1%.
Negatives
- −The company's Return on Capital Employed (ROCE) is 3.79%, which is lower than its Return on Equity.
- −The company recorded a net loss of Rs 10.47 Cr in the Jun 2025 quarter and a net loss of Rs 11.89 Cr in the Sep 2025 quarter.
- −The FII holding is low at 0.91% as of June 30, 2026.
- −The company does not provide a dividend yield (0%).
Financial Performance
Unichem Laboratories Ltd. recorded a revenue of Rs 2264.91 Cr, representing an 18.3% increase. The company's net profit margin was 11.48%. Quarterly revenue for Mar 2026 was Rs 575.12 Cr, with a net profit of Rs 10.91 Cr. The December 2025 quarter saw a net profit of Rs 264.29 Cr on revenue of Rs 521.17 Cr.
Profitability & Returns
The company's Return on Equity (ROE) is 288.1%, while Return on Capital Employed (ROCE) is 3.79%. The EPS for the latest annual period (Mar 2026) was 35.85. The PE ratio stands at 51.21.
Balance Sheet
Unichem Laboratories Ltd. has a book value per share of Rs 385.97. The debt-to-equity ratio is 0.19, indicating a relatively low level of debt. The company does not offer a dividend yield.
Ownership & Pledges
There are no shares pledged by the promoters.
Quarterly Performance
The company reported varying quarterly performance. In Mar 2026, net profit was Rs 10.91 Cr on revenue of Rs 575.12 Cr. In Dec 2025, net profit was Rs 264.29 Cr with revenue of Rs 521.17 Cr. However, June 2025 saw a net loss of Rs 10.47 Cr on revenue of Rs 526.6 Cr and September 2025 saw a net loss of Rs 11.89 Cr on revenue of Rs 578.96 Cr.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.